SERUM CYSTATIN C FOR RISK STRATIFICATION IN PATIENTS WITH PREDIABETES
Abstract
The aim of the investigation is to study the value of Cystatin-C among patients with prediabetes for risk stratification. Material and methods of the study. Our study included 55 people aged 18 to 65 years, including 35 men with an average age of 54.3±3.2 years and 20 women with an average age of 51.1±2.1 years. The study was conducted at the Andijan Regional Endocrinology Dispensary. The control group consisted of 20 healthy people. Research methods: included general clinical methods, biochemical tests (fasting blood glucose level and 2 hours after a meal, glycated hemoglobin, bilirubin, both direct and indirect, ALT, AST, PTI, coagulogram, C-reactive protein, urea, creatinine, lipid spectrum, Cystatin-C), hormonal studies (if necessary, insulin and C-peptide levels in the blood) and instrumental methods: ECG, ultrasound of the endocrine glands and internal organs, chest X-ray and others. Research results. Prediabetes is a risk factor for ASCVD (prediabetes: CI: 1.08–1.15; P < 0.001), chronic kidney disease (prediabetes: CI: 1.02–1.14; P < 0.001; ), and heart failure (prediabetes: CI: 1.01–1.14; P = 0.03; ). Compared with hemoglobin A1c (HbA1c) levels less than 5.0%, covariate-adjusted risks were significantly increased for ASCVD with HbA1c greater than 5.4%, chronic kidney disease greater than 6.2%, and heart failure greater than 7.0 In the same way, the average values of CRP and Cystatin-C were significantly increased in comparison with the control group (p < 0.005). Conclusions: Cystatin C can be used as an early biomarker of chronic kidney disease (CKD) and is associated with prediabetes. It can help identify patients with preclinical kidney disease who are at increased risk of developing chronic kidney disease. Elevated cystatin C levels can detect CKD even in its early stages, when other markers such as creatinine have not yet changed significantly.
Keywords:
About the Authors
List of references
Vart P. et al. National trends in the prevalence of chronic kidney disease among racial/ethnic and socioeconomic status groups, 1988-2016 //JAMA network open. – 2020. – Т. 3. – №. 7. – С. e207932-e207932.
Plantinga L. C. et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes //Clinical Journal of the American Society of Nephrology. – 2010. – Т. 5. – №. 4. – С. 673-682.
Kidney G. Disease: Improving Global Outcomes Diabetes Work,“KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease” //Kidney Int. – 2022. – Т. 102. – С. S1-S127.
American Diabetes Association. 7. Diabetes technology: standards of medical care in diabetes—2021 //Diabetes Care. – 2021. – Т. 44. – №. Supplement_1. – С. S85-S99.
Sallar A., Dagogo-Jack S. Regression from prediabetes to normal glucose regulation: state of the science //Experimental Biology and Medicine. – 2020. – Т. 245. – №. 10. – С. 889-896.
Kalaitzidis R. G., Bakris G. L. Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? //Current opinion in nephrology and hypertension. – 2009. – Т. 18. – №. 5. – С. 386-391.
Kim H. J. et al. Clinical features and predictors of masked uncontrolled hypertension from the Korean Ambulatory Blood Pressure Monitoring Registry //The Korean Journal of Internal Medicine. – 2021. – Т. 36. – №. 5. – С. 1102.
Honigberg MC, Zekavat SM, Pirruccello JP, Natarajan P, Vaduganathan M. Cardiovascular and Kidney Outcomes Across the Glycemic Spectrum: Insights From the UK Biobank. //J Am Coll Cardiol. 2021 Aug 3;78(5):453-464. doi: 10.1016/j.jacc.2021.05.004.
Xiong K, Zhang S, Zhong P, Zhu Z, Chen Y, Huang W, Wang W. Serum cystatin C for risk stratification of prediabetes and diabetes populations. //Diabetes Metab Syndr. 2023 Nov;17(11):102882. doi: 10.1016/j.dsx.2023.102882
Sabanayagam C, Wong TY, Xiao J, Shankar A. Serum cystatin C and prediabetes in non-obese US adults. //Eur J Epidemiol. 2013 Apr;28(4):311-6. doi: 10.1007/s10654-013-9781-3
Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I, Palmas W, Siscovick D, Levey AS, Shlipak MG. Cystatin C identifies chronic kidney disease patients at higher risk for complications.// J Am Soc Nephrol. 2011 Jan;22(1):147-55. doi: 10.1681/ASN.2010050483.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.